Needham & Company LLC Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price

Celcuity (NASDAQ:CELC) had its price target upped by Needham & Company LLC from $95.00 to $122.00 in a report published on Tuesday, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

CELC has been the subject of a number of other research reports. HC Wainwright reaffirmed a “neutral” rating and issued a $94.00 price target (up from $77.00) on shares of Celcuity in a report on Monday, November 17th. Wolfe Research initiated coverage on Celcuity in a research note on Tuesday, November 18th. They set an “outperform” rating and a $110.00 price objective on the stock. Wells Fargo & Company initiated coverage on Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective on the stock. Jefferies Financial Group raised their price objective on Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday, December 2nd. Finally, Stifel Nicolaus lifted their target price on Celcuity from $68.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $108.63.

Celcuity Price Performance

CELC stock opened at $117.10 on Tuesday. Celcuity has a 52 week low of $7.57 and a 52 week high of $120.32. The firm has a market capitalization of $5.42 billion, a P/E ratio of -31.91 and a beta of 0.38. The company has a fifty day simple moving average of $107.98 and a two-hundred day simple moving average of $86.00. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 20,000 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director directly owned 90,000 shares in the company, valued at approximately $10,802,700. This represents a 18.18% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 15.78% of the company’s stock.

Institutional Trading of Celcuity

Several institutional investors have recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC grew its stake in shares of Celcuity by 1,329.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock valued at $34,000 after buying an additional 319 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Celcuity in the fourth quarter worth approximately $42,000. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Celcuity during the 3rd quarter worth approximately $27,000. US Bancorp DE lifted its stake in shares of Celcuity by 25.4% during the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock worth $35,000 after acquiring an additional 143 shares during the last quarter. Finally, NBC Securities Inc. purchased a new position in Celcuity during the 4th quarter valued at $99,000. Institutional investors own 63.33% of the company’s stock.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Publication of Phase 3 VIKTORIA‑1 results — Peer‑reviewed efficacy and safety results for the PIK3CA wild‑type cohort treated with gedatolisib were published in the Journal of Clinical Oncology, validating trial data and increasing visibility for Celcuity’s lead program. This kind of publication can materially de‑risk clinical perception and attract institutional and biotech investors. JCO Publication
• Positive Sentiment: Analyst price‑target upgrade — Needham raised its price target to $122 and reiterated a Buy rating, signalling continued analyst confidence and providing supportive brokerage coverage that can prop up demand. StreetInsider
• Positive Sentiment: Broad media coverage highlighting strong run — Retail and broader market attention (MSN feature noting the company’s large multi‑hundred percent run) can amplify buying interest and momentum trading. Increased coverage often brings new investor inflows. MSN Article
• Neutral Sentiment: Conference presentations/transcripts — Celcuity presented at TD Cowen and Leerink conferences; transcripts offer management commentary and R&D timelines that help investors but typically don’t move the stock unless new data or guidance is disclosed. TD Cowen Transcript
• Neutral Sentiment: Additional conference transcript (Leerink) — Provides more detail on strategy and timelines; useful for due diligence but not headline news. Leerink Transcript
• Neutral Sentiment: Valuation critique piece — A DCF/valuation article highlights divergence between narrative momentum and modelled fair value; useful for longer‑term investors but less likely to halt near‑term momentum. Yahoo Finance Valuation
• Neutral Sentiment: Short‑interest data flagged as increased but shows zero shares — reported short‑interest entries appear inconsistent/erroneous (0 shares reported), so there’s no clear signal of substantial short pressure or squeeze at this time. (Watch for corrected filings.)
• Negative Sentiment: Apís Capital trimmed holdings — A reported reduction by an institutional holder can be a modest headwind and may be interpreted as profit‑taking by some investors; magnitude/context of the trim matters but this is a negative datapoint. Fool: Apis Trim

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.